FNCH - Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07 revenue of $0.36M
- Finch Therapeutics press release ( NASDAQ: FNCH ): Q2 GAAP EPS of -$0.48 misses by $0.07 .
- Revenue of $0.36M (-87.3% Y/Y).
- Finch’s cash and cash equivalents as of June 30, 2022 was $104.7 million, compared to $133.5 million as of December 31, 2021.
- Shares +1.92% PM.
For further details see:
Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M